1. Home
  2. TTRX vs WNEB Comparison

TTRX vs WNEB Comparison

Compare TTRX & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$10.09

Market Cap

298.8M

Sector

Health Care

ML Signal

N/A

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

N/A

Current Price

$14.02

Market Cap

264.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
WNEB
Founded
2015
1853
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
264.8M
IPO Year
2025
2001

Fundamental Metrics

Financial Performance
Metric
TTRX
WNEB
Price
$10.09
$14.02
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
★ $25.00
$15.00
AVG Volume (30 Days)
★ 83.7K
30.8K
Earning Date
11-25-2026
10-27-2026
Dividend Yield
N/A
★ 2.00%
EPS Growth
N/A
★ 33.93
EPS
N/A
★ 0.42
Revenue
N/A
★ $44,000.00
Revenue This Year
N/A
$11.31
Revenue Next Year
$900.00
$8.11
P/E Ratio
★ N/A
$33.26
Revenue Growth
★ N/A
N/A
52 Week Low
$2.57
$11.17
52 Week High
$16.45
$15.01

Technical Indicators

Market Signals
Indicator
TTRX
WNEB
Relative Strength Index (RSI) 42.31 57.01
Support Level $10.05 $13.34
Resistance Level $10.72 $14.13
Average True Range (ATR) 0.78 0.31
MACD -0.02 0.05
Stochastic Oscillator 29.98 64.14

Price Performance

Historical Comparison
TTRX
WNEB

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

Share on Social Networks: